TīmeklisIndication. The Lamira Nebuliser System is indicated to deliver ARIKAYCE liposomal for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by … Tīmeklis2024. gada 23. marts · Starnberg, Germany, March 23rd, 2024 – PARI Pharma GmbH, a company focused on advanced aerosol delivery systems based on eFlow …
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal …
Tīmeklis2024. gada 24. marts · About PARI Pharma and the Lamira ® Nebulizer System. ARIKAYCE is delivered by a novel inhalation device, the Lamira ® Nebulizer System, developed by PARI. Lamira ® is a quiet, portable nebulizer that enables efficient aerosolization of ARIKAYCE via a vibrating, perforated membrane. Based on PARI's … TīmeklisThis will teach you how to prepare, use, and clean the Lamira® Nebulizer System. If you have any questions about use, call your provider or Arikares Support at 1-833 … punchingball boxen
PARI Pharma
Tīmeklis2024. gada 12. maijs · Nebulised liposomal amikacin is given once a day using the Lamira nebuliser system. Treatment may last for up to 18 months if there was a sputum culture conversion response in the first 6 months. This long‑term commitment may have an impact on some people's daily life. The EPAR states that 'the data … TīmeklisArikayce is the first drug with authorisation to be used with the Lamira Nebuliser system specifically for the treatment of patients in Japan with refractory MAC lung disease. *Qualifying persons may obtain medications directly from patient assistance programs without any out-of-pocket cost (or for less than $49 per medication). ... TīmeklisThe purpose of these studies was to understand the effect on product performance of batch-to-batch variability in both the amikacin liposome inhalation suspension (ALIS) formulation and its delivery device, the Lamira® nebulizer system, designed and manufactured by PARI (PARI Pharma GmbH, Munich, Ge … punching bag with stand for kids